ReviewPediatric transplantation2025
Hiding in Plain Sight: Pulmonary Vein Stenosis Following Pediatric Heart Transplantation.
Review in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary vein stenosis (PVS) after pediatric heart transplantation (PHT) is an observed phenomenon with previously unknown incidence, risk factors, treatment, and outcome.
methodsThis is a review of three recent publications describing PVS after PHT.
resultsIn total, 712 PHT recipients from four centers, over a combined 43 years, are reviewed. Thirty-one new cases of PVS after PHT, in addition to six patients with preexisting PVS, are described. PVS diagnosis occurred in the first year after PHT for most patients. Left-sided PVS were more than twice as common as right-sided PVS. Nearly half (43%) experienced multivessel PVS. Major risk factors of PVS after PHT included younger age, history of congenital heart disease (CHD), and history of anomalous pulmonary venous return. The treatment of PVS after PHT varied, reflecting uncertainty in the management of PVS generally. With a median follow-up of less than 3 years, 19% of patients with PVS after PHT died.
conclusionsPVS after PHT complicated approximately 4.4% of cases in these reports. PVS is more common after PHT in younger patients with a history of CHD. PVS is generally diagnosed in the first year after PHT. We recommend careful evaluation for PVS in the first year after PHT in patients with known risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.